Minimal differences were noted in IFNγ, TNFα, Granzyme B, and CD107B expression when comparing CD4+ T cells from glioma patients before and after M032 treatment [Figures 6A and B]; however, a significant reduction in IL-4 production between pre- and post-M032 treatment in peripheral blood CD4+ T cells was noted [Figure 6C]. This evidence concerns the gene CD4 and central nervous system cancer.